Form 4: VolitionRX Executive Receives Stock Award in Lieu of Cash Compensation

Rodney Gerard Rootsaert, Secretary of VolitionRX Ltd, received 15,258 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

Summary

• On September 1, 2024, Rodney Gerard Rootsaert, Secretary of VolitionRX Ltd, was granted 15,258 restricted stock units (RSUs) under the company's 2015 Stock Incentive Plan.
• These RSUs were awarded in place of cash compensation.
• The RSUs vest in three equal installments of 5,086 units on September 1, 2024, October 1, 2024, and November 1, 2024.
• The RSUs are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date.
• Upon vesting and settlement, Rootsaert will receive common stock shares equal to the number of vested RSUs.
• Rootsaert also indirectly owns 1,007,718 shares of common stock through Concord International, Inc., where he is a controlling director.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates continued employment and alignment of interests.

Positives

• The award of RSUs aligns the executive's interests with those of the shareholders.
• Using RSUs instead of cash may preserve the company's cash reserves.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock awards are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns executive compensation with company performance.
• Employees may see the RSU grant as a positive sign of the company's commitment to its employees.

Key Dates